Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

EISAI CO., LTD (4523)
Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Eisai : clinches Merck deal to develop and sell cancer drug, shares soar

share with twitter share with LinkedIn share with facebook
share via e-mail
03/08/2018 | 08:30am CET
Eisai Co Ltd Representative Corporate Officer and CEO Haruo Naito attends a news conference at the company headquarters in Tokyo

NEW YORK/TOKYO (Reuters) - Merck & Co Inc and Japan's Eisai Co Ltd have signed a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses.

The deal, under which Lenvima will be developed for several types of cancer alone and in combination with Merck's immunotherapy Keytruda, could be worth up to $5.76 billion (4.14 billion pounds) to Eisai, but most of that would be contingent on eventual sales.

Eisai shares surged 10 percent on the news, with the Japanese drugmaker saying Lenvima may become a blockbuster drug generating annual sales of at least $1 billion in the year ending March 2021.

U.S. drugmaker Merck will be entitled to half of all global Lenvima sales revenue, even for its already approved uses for thyroid cancer and in combination with another drug for kidney cancer.

The deal is similar to a multibillion-dollar oncology collaboration Merck struck with AstraZeneca Plc on its cancer drug Lynparza and another medicine last July.

"Like the Lynparza deal with AstraZeneca, this starts to really broaden out Merck's portfolio," Frank Clyburn, head of Merck's commercial oncology business, said in an interview. "And Merck will start to receive revenue right away."

Under the deal, Eisai will receive an upfront payment of $300 million and up to $650 million for certain option rights through March 2021. Eisai could receive another $385 million in clinical and regulatory milestones, while Merck will receive $450 million as reimbursement for research and development costs.

The collaboration gives Eisai access to Merck's R&D and sales clout as well as a means of maximizing the potential of Lenvima in combination with the leading immunotherapy drug.

Following positive trial data showing that Lenvima with Keytruda led to tumor shrinkage in 63 percent of advanced kidney cancer patients, the combination received breakthrough designation from the U.S. Food and Drug Administration.

The combination also appeared to enhance the impact of Keytruda on advanced kidney cancer.

Breakthrough status is a designation given to treatments demonstrating substantial improvement over existing therapies in treating a serious or life threatening illness.

The companies said they will develop the combination for 11 different potential uses across six other cancer types, including skin cancer and bladder cancer.

"It makes sense ... to try to develop the drug to the full extent possible as monotherapy and in combination with Keytruda," Roger Perlmutter, president of Merck Research Laboratories, said in an interview.

Lenvima, an oral drug known chemically as lenvatinib, was discovered by Eisai scientists and belongs to a class of medicines known as tyrosine kinase inhibitors that block the blood vessel supply to tumors and tumor growth.

The injection of funds following the deal will be used to accelerate research and development of treatments for Alzheimer's disease and cancer, Eisai Chief Executive Haruo Naito told a news conference in Tokyo.

Eisai's shares, currently worth some $17 billion, have been hit in recent months by setbacks for two Alzheimer's drugs in development with Biogen Inc.

One drug, BAN2401, failed to meet the main goal of a mid-stage trial, Biogen said in December. In February, the U.S. drugmaker said it was enrolling more patients for its late-stage trial drug aducanumab, heightening concerns about the challenges of Alzheimer's drug studies.

(Reporting by Bill Berkrot in New York and Sam Nussey in Tokyo; Additional reporting by Chang-Ran Kim, Minami Funakoshi in Tokyo; Editing by Lisa Shumaker and Edwina Gibbs)

By Bill Berkrot and Sam Nussey

Stocks treated in this article : Merck and Company, Eisai Co., Ltd
Stocks mentioned in the article
ChangeLast1st jan.
MERCK AND COMPANY 0.00% 54.7 Delayed Quote.-2.81%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on EISAI CO., LTD
03/19EISAI : Launches gastrointestinal prokinetic agent cidine in china
03/19ARENA PHARMACEUTICALS : Provides Corporate Update and Reports Fourth Quarter and..
03/15EISAI : and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® len..
03/14MERCK AND : Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaborat..
03/14EISAI : Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen ..
03/13EISAI : and Purdue Pharma Announce Positive Topline Results From Key Clinical St..
03/12EISAI : H3 Biomedicine to Present at the Cowen Annual Health Care Conference
03/09MERCK AND : $5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima
03/08EISAI : Merck in global oncology deal
03/08EISAI : agrees with Merck on potential $5.76 bil. cancer drugs deal
More news
News from SeekingAlpha
03/12Eisai (ESALF) Investor Presentation - Slideshow 
03/08Merck (MRK) Teams Up With Eisai (ESALY) To Commercialize Cancer Med Lenvima -.. 
03/08Merck teams up with Eisai to commercialize cancer med Lenvima in deal valued .. 
03/07Eisai's lemborexant matches Sanofi's extended-release Ambien in late-stage sl.. 
02/15FDA issues draft industry guidance for early-stage Alzheimer's disease 
Financials ( JPY)
Sales 2018 596 B
EBIT 2018 -
Net income 2018 51 676 M
Debt 2018 4 412 M
Yield 2018 2,20%
P/E ratio 2018 37,07
P/E ratio 2019 39,97
EV / Sales 2018 3,40x
EV / Sales 2019 3,36x
Capitalization 2 019 B
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | 4523 | JP3160400002 | 4-Traders
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 11
Average target price 6 891  JPY
Spread / Average Target 1,2%
EPS Revisions
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD4.79%19 068
JOHNSON & JOHNSON-6.09%351 989
PFIZER0.30%216 268
NOVARTIS-5.95%212 073
ROCHE HOLDING LTD.-11.12%198 243
MERCK AND COMPANY-2.81%147 455